EBR Systems Reports $17.1 Million Net Loss in Q1 2026, Revenue from WiSE CRT System

EBR Systems, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $17.1 million, a 61.8% increase from the $10.6 million loss recorded in the same period of 2025. The company's revenue for the quarter reached $2.4 million, attributed to the commercialization of its WiSE CRT System, which received FDA approval in April 2025. This marks a significant milestone for EBR, as it had no revenue in the prior year’s quarter. The cost of goods sold was $2.2 million, resulting in a gross profit of $184,000 and a gross margin of 7.8%.

The increase in net loss was primarily driven by a substantial rise in operating expenses, which totaled $16.4 million, up 67.2% from $9.8 million in the previous year. Research and development expenses rose by 18.4% to $6.4 million, while selling, general, and administrative expenses surged by 127.8% to $9.9 million. The latter increase was largely due to expanded personnel costs and increased travel expenses to support sales and marketing efforts. Additionally, the company experienced a decrease in interest income, contributing to the overall increase in losses.

Operationally, EBR Systems reported 41 commercial implants of the WiSE CRT System across 19 hospitals in the U.S. during the quarter. The company also trained 22 new physicians to implant the device and signed 16 additional purchase agreements with targeted sites. As of March 31, 2026, EBR had approximately $30.9 million in cash, cash equivalents, and marketable securities, down from $54.2 million at the end of 2025. The decrease in cash reserves reflects ongoing operational losses and capital expenditures.

EBR's balance sheet showed total assets of $80.3 million, down from $97.2 million at the end of 2025, with total liabilities slightly decreasing to $70.7 million. The company’s accumulated deficit increased to $419.3 million. EBR is currently evaluating its capital needs, as it anticipates continued operating losses and negative cash flows in the near future. The company has expressed substantial doubt about its ability to continue as a going concern for at least the next twelve months unless it can secure additional funding.

Looking ahead, EBR Systems plans to focus on expanding its sales force and marketing efforts to drive adoption of the WiSE CRT System. The company aims to increase awareness among healthcare providers and expand its customer base, both domestically and internationally. However, the success of these initiatives remains uncertain, and the company will need to navigate various market and regulatory challenges to achieve its growth objectives.